Predictors of the Effect of Tolvaptan on the Prognosis of Cirrhosis

Objective Tolvaptan was first approved for use for cirrhosis in Japan in September 2013. The aim of the study was to examine the effect of tolvaptan, a vasopressin V2 receptor antagonist, on the prognosis of cirrhosis. Methods The effect of tolvaptan was evaluated in 26 patients with cirrhosis treat...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Intern Med
Main Authors: Iwamoto, Takuya, Maeda, Masaki, Hisanaga, Takuro, Saeki, Issei, Fujisawa, Koichi, Matsumoto, Toshihiko, Hidaka, Isao, Ishikawa, Tsuyoshi, Takami, Taro, Sakaida, Isao
Format: Artigo
Jezik:Inglês
Izdano: The Japanese Society of Internal Medicine 2016
Teme:
Original Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5109555/
https://ncbi.nlm.nih.gov/pubmed/27746425
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki